# Vaccine Therapy in Treating Patients With Stage IV Melanoma

> **NCT00003665** · PHASE1 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 40 (actual)

## Conditions studied

- Melanoma (Skin)

## Interventions

- **BIOLOGICAL:** dendritic cell-MART-1 peptide vaccine
- **BIOLOGICAL:** gp100 antigen
- **BIOLOGICAL:** therapeutic tumor infiltrating lymphocytes
- **BIOLOGICAL:** tyrosinase peptide

## Key facts

- **NCT ID:** NCT00003665
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1999-04
- **Primary completion:** 2002-10
- **Final completion:** 2002-11
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2013-02-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00003665

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00003665, "Vaccine Therapy in Treating Patients With Stage IV Melanoma". Retrieved via AI Analytics 2026-06-13 from https://api.ai-analytics.org/clinical/NCT00003665. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*